Can I drive after taking medicinal cannabis in NSW right now?

Under current NSW law, any detectable THC in a roadside saliva test is an offence — regardless of whether you are impaired, and regardless of whether you have a valid prescription. The proposed bill has not yet passed. Until the law changes, the safest advice is to wait at least six to eight hours after using any THC-containing medicinal cannabis product before driving, and to not drive if you feel any impairment at all.

My GP prescribed medicinal cannabis for chronic pain — do I have to tell them about the new laws?

It is worth raising at your next appointment. Your prescribing GP should be part of an ongoing conversation about fitness to drive. If you drive for work or commute regularly, the question of how your medicinal cannabis prescription intersects with road safety is a legitimate clinical discussion — not just a legal one. Your GP can help you think through timing, dosing, and whether your current regimen is compatible with safe driving.

NSW medicinal cannabis driving bill: what GPs need to know now

What just happened

NSW has introduced a bill that would change how the state handles medicinal cannabis patients in roadside drug testing. If passed, the proposed legislation would replace the current zero-tolerance framework — where any detectable THC in a roadside saliva test constitutes an offence — with a graduated response system built around actual laboratory results and clinical fitness criteria.

The bill was lodged in NSW Parliament on 25 June 2026. Parliamentary debate is scheduled for August 2026. Nothing has changed in law yet. GPs and patients should advise and act under current rules until further notice.

Under the proposed framework:

A positive roadside saliva test results in a 24-hour licence suspension pending laboratory confirmation
Laboratory results below 50 ng/mL THC allow the patient to resume driving
Results above 50 ng/mL prompt a requirement to consult a prescribing doctor about medication adjustment
A three-strike rule applies: a third positive test within two years — regardless of whether impairment is demonstrated — triggers potential offence charges
Mandatory registration, prescription verification, and compulsory patient education requirements would apply across the board for medicinal cannabis prescriptions

The registration model draws on precedents from existing frameworks for other medications affecting fitness to drive, such as opioid prescribing for chronic pain.

The both-and

Why zero-tolerance was always the wrong frame for medicinal cannabis patients

The current framework made sense when designed — for recreational cannabis, where a positive saliva test correlates reasonably well with recent use and likely impairment. Medicinal cannabis patients present a fundamentally different clinical picture.

THC is detectable in saliva for periods ranging from hours to more than a day, depending on the formulation, dose, route of administration, and individual metabolic variation. A patient using a CBD-dominant oil with a low THC content for chronic pain, taken the previous evening, may produce a positive roadside swab without any residual effect on driving capacity by the following morning. Under current NSW law, that patient faces a penalty identical to someone who smoked cannabis an hour before driving.

Associate Professor Vicki Kotsirilos, quoted in Medical Republic coverage of the bill, described the existing framework as “frustrating and unjust” for patients using medicinal cannabis lawfully and under medical supervision. Her core clinical advice — wait six to eight hours after use before driving, avoid concurrent alcohol and sedating medications, use the lowest effective dose, and not drive if any sense of impairment is present — remains the right standard regardless of what the law says or what it becomes.

The 50 ng/mL threshold needs scrutiny

The bill’s proposed laboratory threshold of 50 ng/mL is the element that will generate the most discussion before and during the August debate, and rightly so. The number is not arbitrary, but the research connecting a specific saliva THC concentration to demonstrable driving impairment in medicinal cannabis patients is not yet settled. Different formulations, different patient tolerances, and different use patterns produce very different pharmacokinetic profiles.

What the 50 ng/mL threshold does is establish a line in the absence of a perfect one — a pragmatic compromise that attempts to distinguish patients from recreational users without requiring impairment to be directly measured at the roadside. The alternative, direct impairment testing (cognitive performance assessment, physiological signs), exists but is operationally complex and not yet validated for roadside use at scale.

For prescribing GPs, the message is that the threshold, if enacted, still does not protect every patient — someone prescribed a higher-dose THC product may still exceed 50 ng/mL several hours after last use and within their subjective normal functioning. The clinical conversation about driving and medicinal cannabis needs to be individualised, not replaced by a number.

NSW as a potential policy catalyst

If this bill passes in its current form, NSW becomes the first Australian state to implement a fitness-to-drive framework for medicinal cannabis rather than a zero-tolerance approach. Victoria and Queensland have faced significant patient advocacy pressure to move in the same direction; Western Australia and South Australia have had similar calls from prescribers. Whether the NSW model performs as intended — reducing unjust penalties for compliant patients while preserving deterrence of genuinely impaired driving — will shape the national policy landscape.

The TGA’s regulatory framework for medicinal cannabis access has expanded significantly since the SAS-B and authorised prescriber pathways were established. The volume of patients now being prescribed THC-containing products through general practice has grown substantially. The road law is the last major point of friction for many of those patients.

2 cents

If you are a patient in NSW taking any THC-containing medicinal cannabis product and you drive, current law applies in full — the proposed bill is not yet in effect. The safest approach right now is the same as it has always been: wait at least six to eight hours after your last dose, and do not drive if there is any subjective sense of impairment.

If driving is essential to your work or daily life, raise the timing question explicitly with your prescribing GP. It is a legitimate clinical discussion, and the right dosing schedule may be adjustable in a way that reduces your risk under current law.

The Medical Republic’s framing — “welcome but safeguards needed” — is the right read on this bill. The direction is overdue. The details still need work.

Verdict: maybe — important to watch, not yet law.

Sources cited

Medical Republic — New medcann driving laws welcome but safeguards needed. 1 July 2026. https://www.medicalrepublic.com.au/new-medcann-driving-laws-welcome-but-safeguards-needed/126917
Therapeutic Goods Administration — Medicinal cannabis. https://www.tga.gov.au/products/medicinal-cannabis
RACGP — Medicinal Cannabis in General Practice. https://www1.racgp.org.au/getattachment/Policies/Policies/Clinical/Medicinal-Cannabis/Medicinal-Cannabis-in-General-Practice.pdf